Compare Infosys Limited (INFY) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Kymera Therapeutics Inc. Common Stock — how do they compare? Infosys Limited trades at $11.7 (market cap $44.92B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Infosys Limited is far larger — about 5.1× Kymera Therapeutics Inc. Common Stock's market cap, and Infosys Limited pays a 4.59% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 26 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| INFY | KYMR | |
|---|---|---|
Market Cap | $44.92B | $8.87B |
Volume | 25,564,570 | 779,107 |
Sector | Technology | Health |
52-Week High | $20.22 | $127.31 |
52-Week Low | $10.49 | $55.80 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $42.66B | $8.26B |
Dividend Yield | 4.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $11.40, up 5.26% today, with a bullish technical signal driven by oversold RSI conditions. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 exceeding expectations. Revenue for 2025 was $19.28B, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations with Columbia University and ABN Amro, positioning the firm for innovation-driven growth.
The outlook is cautiously optimistic, supported by solid profitability and strategic partnerships, but tempered by a mixed analyst consensus and potential net cash flow decline in 2026. Key risks include competitive pressures in IT services and macroeconomic sensitivity. The consensus price target of $11.48 suggests limited near-term upside from current levels.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
